Dr. Ryan is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
601 Elmwood Ave
University Of Rochester Medical Center; Box 608
Rochester, NY 14642Phone+1 585-275-3184
Education & Training
University of RochesterResidency, Pathology-Anatomic and Clinical, 1976 - 1981
University of Rochester Medical CenterInternship, Transitional Year, 1975 - 1976
Johns Hopkins University School of MedicineClass of 1975
Certifications & Licensure
NY State Medical License 1980 - 2026- American Board of Pathology Anatomic Pathology & Clinical Pathology
Awards, Honors, & Recognition
- Top MD Consumers Checkbook
Publications & Presentations
PubMed
- 81 citationsCPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a ra...Jeffrey E. Lancet, Geoffrey L. Uy, Laura F. Newell, Tara L. Lin, Ellen K. Ritchie
The Lancet. Haematology. 2021-07-01 - 12 citationsOlder adults with newly diagnosed high-risk/secondary AML who achieved remission with CPX-351: Phase 3 post hoc analysesTara L. Lin, David A. Rizzieri, Daniel H. Ryan, Gary J. Schiller, Jonathan E. Kolitz
Blood Advances. 2021-03-23 - 19 citationsIs the prescription right? A review of non-vitamin K antagonist anticoagulant (NOAC) prescriptions in patients with non-valvular atrial fibrillation. Safe prescribing ...Rebabonye B. Pharithi, Deepti Ranganathan, James O’Brien, Emmanuel E. Egom, Cathie Burke
Irish Journal of Medical Science. 2019-02-01
Abstracts/Posters
- Phase 3 Exploratory Analysis of Outcomes in Patients with Acute Myeloid Leukemia with Myelodysplasia-Related Changes (AML-MRC) Who Received Consolidation with CPX-351 ...Daniel H. Ryan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Efficacy and Safety of CPX-351 Versus 7+3 in a Phase 3 Exploratory Analysis in Patients with High-Risk/Secondary Acute Myeloid Leukemia (AML) with Prior Hypomethylatin...Daniel H. Ryan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Press Mentions
September 5, 2020September 5th, 2020
Grant Support
- B Lineage Development Of Human Hematopoietic ProgenitorsNational Cancer Institute1998–2000
- Biology Of Calla + Cells In Lymphoblastic LeukemiaNational Cancer Institute1985–1987
Professional Memberships
- Association of Pathology ChairsFellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
